Company Name: Minomic
Announcement Date: 21/07/2016
Announcement Category: Product launch/update
Announcement Content:
Australian biotech company Minomic has developed a non-invasive test, Mi-Check, to detect prostate cancer. PSA testing typically returns 6 false positive results out of 10, resulting in unnecessary biopsies, meaning stress, pain and the risk of infection. Trials indicate Mi-Check returns just 1.5 false positives out of 10. Please watch Minomic's CEO, Dr Brad Walsh, for more details.
Announcement URL: http://bit.ly/29WG238
About Minomic:
Minomic has developed a new, non-invasive test for prostate cancer, called MiCheck. Using only a simple blood sample, the MiCheck test detects a protein that is present on cancer cells.
It's more specific than existing tests like the PSA test, therefore, once commercialised, would reduce the rate of false positive results and unnecessary biopsies. Fewer biopsies performed means a reduced risk of infection, less time off work and a substantially reduced economic burden on the health system.
Go to Company Profile for: Minomic
Announcement Contact: [email protected]
